Abbott Laboratories (ABT) : Pictet North America Advisors Sa scooped up 5,805 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 10, 2016. The investment management firm now holds a total of 25,031 shares of Abbott Laboratories which is valued at $1,127,396.Abbott Laboratories makes up approximately 0.25% of Pictet North America Advisors Sa’s portfolio.
Other Hedge Funds, Including , Homrich Berg reduced its stake in ABT by selling 177 shares or 2.77% in the most recent quarter. The Hedge Fund company now holds 6,212 shares of ABT which is valued at $279,788. Abbott Laboratories makes up approx 0.03% of Homrich Berg’s portfolio.Peak Asset Management boosted its stake in ABT in the latest quarter, The investment management firm added 2,700 additional shares and now holds a total of 18,233 shares of Abbott Laboratories which is valued at $819,573. Abbott Laboratories makes up approx 0.17% of Peak Asset Management’s portfolio.Tarbox Group boosted its stake in ABT in the latest quarter, The investment management firm added 15 additional shares and now holds a total of 53,497 shares of Abbott Laboratories which is valued at $2,393,991. Abbott Laboratories makes up approx 1.65% of Tarbox Group’s portfolio.
Abbott Laboratories closed down -0.12 points or -0.27% at $44.24 with 94,39,877 shares getting traded on Friday. Post opening the session at $44.17, the shares hit an intraday low of $43.645 and an intraday high of $44.31 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.